This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



mogamulizumab (Poteligeo®)


Reference No. 2792

Publication date:
14/05/2019


Appraisal information

mogamulizumab (Poteligeo®) 4 mg/ml concentrate for solution for infusion
mogamulizumab (Poteligeo®) Unspecified


Company: Kyowa Kirin Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/05/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, mogamulizumab (Poteligeo®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with mycosis fungoides or Sezary syndrome who have received at least one prior systemic therapy
Statement of Advice (SOA)
Download